SCHEMBL18979086

SCHEMBL18979086

COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCC(N)=O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.74
EGFR P00533 9/20 0.74
RET P07949 2/20 0.74
KIF5B P33176 2/20 0.74
HDAC3 O15379 8/20 0.69
HDAC4 P56524 8/20 0.69
HDAC1 Q13547 8/20 0.69
HDAC7 Q8WUI4 8/20 0.69
HDAC2 Q92769 8/20 0.69
HDAC10 Q969S8 8/20 0.69
HDAC11 Q96DB2 8/20 0.69
HDAC8 Q9BY41 8/20 0.69
HDAC6 Q9UBN7 8/20 0.69
HDAC9 Q9UKV0 8/20 0.69
HDAC5 Q9UQL6 8/20 0.69
FGFR1 P11362 7/20 0.67
FLT1 P17948 7/20 0.67
FLT4 P35916 6/20 0.67
PDGFRB P09619 2/20 0.66
FGFR2 P21802 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17520358 0.97 KDR (0.73) KDREGFRRETKIF5BHDAC3
SCHEMBL17520354 0.96 KDR (0.71) KDREGFRRETKIF5BHDAC3
SCHEMBL17520330 0.96 KDR (0.74) KDREGFRRETKIF5BHDAC3
SCHEMBL19220792 0.91 KDR (0.69) KDREGFRRETKIF5BHDAC3
SCHEMBL4109645 0.89 KDR (0.80) KDREGFRRETKIF5BHDAC3
SCHEMBL19220786 0.88 HDAC3 (0.69) KDREGFRHDAC3HDAC4HDAC1
SCHEMBL17520353 0.88 KDR (0.73) KDREGFRRETKIF5BHDAC3
SCHEMBL14964748 0.88 KDR (0.82) KDREGFRRETKIF5BFGFR1
SCHEMBL1468281 0.88 KDR (0.82) KDREGFRRETKIF5BFGFR1
SCHEMBL19220774 0.87 HDAC3 (0.70) KDREGFRHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 EP disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
CN-106660970-B Quinazoline derivatives 石药集团中奇制药技术(石家庄)有限公司 2020-07-10 CN disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
EP-3181554-A1 QUINAZOLINE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774079-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 KDR 3669/4885EGFR 3701/4885RET 4595/4885
US-10421754-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 KDR 3669/4885EGFR 3701/4885RET 4595/4885
US-20170226099-A1 QUINAZOLINE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 KDR 3669/4885EGFR 3701/4885RET 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.